Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 226

1.

Noninvasive 11C-rifampin positron emission tomography reveals drug biodistribution in tuberculous meningitis.

Tucker EW, Guglieri-Lopez B, Ordonez AA, Ritchie B, Klunk MH, Sharma R, Chang YS, Sanchez-Bautista J, Frey S, Lodge MA, Rowe SP, Holt DP, Gobburu JVS, Peloquin CA, Mathews WB, Dannals RF, Pardo CA, Kannan S, Ivaturi VD, Jain SK.

Sci Transl Med. 2018 Dec 5;10(470). pii: eaau0965. doi: 10.1126/scitranslmed.aau0965.

PMID:
30518610
2.

Effect of rifampin/isoniazid-containing antituberculosis therapy on efavirenz pharmacokinetics in HIV-infected children aged 3 to 14 years old.

Kwara A, Yang H, Antwi S, Enimil A, Gillani FS, Dompreh A, Ortsin A, Opoku T, Bosomtwe D, Sarfo A, Wiesner L, Norman J, Alghamdi WA, Langaee T, Peloquin CA, Court MH, Greenblatt DJ.

Antimicrob Agents Chemother. 2018 Nov 5. pii: AAC.01657-18. doi: 10.1128/AAC.01657-18. [Epub ahead of print]

3.

Pharmacokinetics of First-Line Drugs Among Children With Tuberculosis in Rural Tanzania.

Justine M, Yeconia A, Nicodemu I, Augustino D, Gratz J, Mduma E, Heysell SK, Kivuyo S, Mfinanga S, Peloquin CA, Zagurski T, Kibiki GS, Mmbaga B, Houpt ER, Thomas TA.

J Pediatric Infect Dis Soc. 2018 Nov 5. doi: 10.1093/jpids/piy106. [Epub ahead of print]

PMID:
30395239
4.

Dose Optimization of Moxifloxacin and Linezolid Against Tuberculosis Using Mathematical Modeling and Simulation.

Heinrichs MT, Drusano GL, Brown DL, Maynard MS, Sy SKB, Rand KH, Peloquin CA, Louie A, Derendorf H.

Int J Antimicrob Agents. 2018 Oct 29. pii: S0924-8579(18)30304-2. doi: 10.1016/j.ijantimicag.2018.10.012. [Epub ahead of print]

PMID:
30385322
5.

Population Pharmacokinetic Model and Limited Sampling Strategies for Personalized Dosing of Levofloxacin in Tuberculosis Patients.

van den Elsen SHJ, Sturkenboom MGG, Van't Boveneind-Vrubleuskaya N, Skrahina A, van der Werf TS, Heysell SK, Mpagama S, Migliori GB, Peloquin CA, Touw DJ, Alffenaar JC.

Antimicrob Agents Chemother. 2018 Nov 26;62(12). pii: e01092-18. doi: 10.1128/AAC.01092-18. Print 2018 Dec.

PMID:
30373800
6.

Training a Drug to Do New Tricks: Insights on Stability of Meropenem Administered as a Continuous Infusion.

Venugopalan V, Manigaba K, Borgert SJ, Cope J, Peloquin CA, Klinker KP.

Microbiol Insights. 2018 Oct 14;11:1178636118804549. doi: 10.1177/1178636118804549. eCollection 2018.

7.

A PRELIMINARY ANALYSIS OF PROLONGED ABSORPTION RATE OF PONAZURIL IN RED-FOOTED TORTOISES, CHELONOIDIS CARBONARIA.

Benge SL, Heinrichs MT, Crevasse SE, Mahjoub B, Peloquin CA, Wellehan JFX Jr.

J Zoo Wildl Med. 2018 Sep;49(3):802-805. doi: 10.1638/2017-0178.1.

PMID:
30212324
8.

Increased Doses Lead to Higher Drug Exposures of Levofloxacin for Treatment of Tuberculosis.

Peloquin CA, Phillips PPJ, Mitnick CD, Eisenach K, Patientia RF, Lecca L, Gotuzzo E, Gandhi NR, Butler D, Diacon AH, Martel B, Santillan J, Hunt KR, Vargas D, von Groote-Bidlingmaier F, Seas C, Dianis N, Moreno-Martinez A, Kaur P, Horsburgh CR Jr.

Antimicrob Agents Chemother. 2018 Sep 24;62(10). pii: e00770-18. doi: 10.1128/AAC.00770-18. Print 2018 Oct.

PMID:
30012767
9.

Efficacy and Safety of High-Dose Rifampin in Pulmonary Tuberculosis. A Randomized Controlled Trial.

Velásquez GE, Brooks MB, Coit JM, Pertinez H, Vargas Vásquez D, Sánchez Garavito E, Calderón RI, Jiménez J, Tintaya K, Peloquin CA, Osso E, Tierney DB, Seung KJ, Lecca L, Davies GR, Mitnick CD.

Am J Respir Crit Care Med. 2018 Sep 1;198(5):657-666. doi: 10.1164/rccm.201712-2524OC.

PMID:
29954183
10.

Evaluation of the Adequacy of WHO Revised Dosages of the First-Line Antituberculosis Drugs in Children with Tuberculosis Using Population Pharmacokinetic Modeling and Simulations.

Horita Y, Alsultan A, Kwara A, Antwi S, Enimil A, Ortsin A, Dompreh A, Yang H, Wiesner L, Peloquin CA.

Antimicrob Agents Chemother. 2018 Aug 27;62(9). pii: e00008-18. doi: 10.1128/AAC.00008-18. Print 2018 Sep.

PMID:
29914960
11.

Mycobacterium tuberculosis Strains H37ra and H37rv have equivalent minimum inhibitory concentrations to most antituberculosis drugs.

Heinrichs MT, May RJ, Heider F, Reimers T, B Sy SK, Peloquin CA, Derendorf H.

Int J Mycobacteriol. 2018 Apr-Jun;7(2):156-161. doi: 10.4103/ijmy.ijmy_33_18.

12.

Perspectives for personalized therapy for patients with multidrug-resistant tuberculosis.

Lange C, Alghamdi WA, Al-Shaer MH, Brighenti S, Diacon AH, DiNardo AR, Grobbel HP, Gröschel MI, von Groote-Bidlingmaier F, Hauptmann M, Heyckendorf J, Köhler N, Kohl TA, Merker M, Niemann S, Peloquin CA, Reimann M, Schaible UE, Schaub D, Schleusener V, Thye T, Schön T.

J Intern Med. 2018 May 28. doi: 10.1111/joim.12780. [Epub ahead of print]

PMID:
29806961
13.

Protein Binding of First-Line Antituberculosis Drugs.

Alghamdi WA, Al-Shaer MH, Peloquin CA.

Antimicrob Agents Chemother. 2018 Jun 26;62(7). pii: e00641-18. doi: 10.1128/AAC.00641-18. Print 2018 Jul.

PMID:
29735566
14.

Pharmacokinetics of tuberculosis drugs in HIV-infected patients from Irkutsk, Russian Federation: redefining drug activity.

Lyles G, Ogarkov O, Zhdanova S, Peloquin CA, Ebers A, Pfaeffle H, Al-Shaer MH, Moiseeva E, Zorkaltseva E, Koscheev M, Houpt ER, Heysell SK.

Eur Respir J. 2018 May 24;51(5). pii: 1800109. doi: 10.1183/13993003.00109-2018. Print 2018 May. No abstract available.

15.

Elevated Plasma Moxifloxacin Concentrations and SLCO1B1 g.-11187G>A Polymorphism in Adults with Pulmonary Tuberculosis.

Weiner M, Gelfond J, Johnson-Pais TL, Engle M, Peloquin CA, Johnson JL, Sizemore EE, Mac Kenzie WR.

Antimicrob Agents Chemother. 2018 Apr 26;62(5). pii: e01802-17. doi: 10.1128/AAC.01802-17. Print 2018 May.

16.

A comparison of linezolid lung tissue concentrations among patients with drug-resistant tuberculosis.

Kempker RR, Heinrichs MT, Nikolaishvili K, Sabulua I, Bablishvili N, Gogishvili S, Avaliani Z, Little BP, Bernheim A, Derendorf H, Blumberg HM, Vashakidze S, Peloquin CA.

Eur Respir J. 2018 Feb 7;51(2). pii: 1702166. doi: 10.1183/13993003.02166-2017. Print 2018 Feb. No abstract available.

PMID:
29437945
17.

Making optimal use of available anti-tuberculosis drugs: first steps to investigate terizidone.

Alffenaar JWC, Peloquin CA, Migliori GB.

Int J Tuberc Lung Dis. 2018 Jan 1;22(1):2. doi: 10.5588/ijtld.17.0632. No abstract available.

PMID:
29297417
18.

Erratum for Alsultan et al., "Population Pharmacokinetics of AZD-5847 in Adults with Pulmonary Tuberculosis".

Alsultan A, Furin JJ, Du Bois J, van Brakel E, Chheng P, Venter A, Thiel B, Debanne SA, Boom WH, Diacon AH, Johnson JL, Peloquin CA.

Antimicrob Agents Chemother. 2017 Dec 21;62(1). pii: e02229-17. doi: 10.1128/AAC.02229-17. Print 2018 Jan. No abstract available.

19.

Reply to Chang et al., "Pyrazinamide Is a Two-Edged Sword: Do WHO Guidelines Matter?"

Peloquin CA, Kempker RR.

Antimicrob Agents Chemother. 2017 Dec 21;62(1). pii: e01937-17. doi: 10.1128/AAC.01937-17. Print 2018 Jan. No abstract available.

20.

Effect of Genetic Variation of NAT2 on Isoniazid and SLCO1B1 and CES2 on Rifampin Pharmacokinetics in Ghanaian Children with Tuberculosis.

Dompreh A, Tang X, Zhou J, Yang H, Topletz A, Adu Ahwireng E, Antwi S, Enimil A, Langaee T, Peloquin CA, Court MH, Kwara A.

Antimicrob Agents Chemother. 2018 Feb 23;62(3). pii: e02099-17. doi: 10.1128/AAC.02099-17. Print 2018 Mar.

21.

Moxifloxacin target site concentrations in patients with pulmonary TB utilizing microdialysis: a clinical pharmacokinetic study.

Heinrichs MT, Vashakidze S, Nikolaishvili K, Sabulua I, Tukvadze N, Bablishvili N, Gogishvili S, Little BP, Bernheim A, Guarner J, Peloquin CA, Blumberg HM, Derendorf H, Kempker RR.

J Antimicrob Chemother. 2018 Feb 1;73(2):477-483. doi: 10.1093/jac/dkx421.

PMID:
29186509
22.

An optimized background regimen design to evaluate the contribution of levofloxacin to multidrug-resistant tuberculosis treatment regimens: study protocol for a randomized controlled trial.

Bouton TC, Phillips PPJ, Mitnick CD, Peloquin CA, Eisenach K, Patientia RF, Lecca L, Gotuzzo E, Gandhi NR, Butler D, Diacon AH, Martel B, Santillan J, Hunt KR, Vargas D, von Groote-Bidlingmaier F, Seas C, Dianis N, Moreno-Martinez A, Horsburgh CR Jr.

Trials. 2017 Nov 25;18(1):563. doi: 10.1186/s13063-017-2292-x.

23.

Verapamil Increases the Bioavailability and Efficacy of Bedaquiline but Not Clofazimine in a Murine Model of Tuberculosis.

Xu J, Tasneen R, Peloquin CA, Almeida DV, Li SY, Barnes-Boyle K, Lu Y, Nuermberger E.

Antimicrob Agents Chemother. 2017 Dec 21;62(1). pii: e01692-17. doi: 10.1128/AAC.01692-17. Print 2018 Jan.

24.

Erratum for Peloquin et al., "Pharmacokinetic Evidence from the HIRIF Trial To Support Increased Doses of Rifampin for Tuberculosis".

Peloquin CA, Velásquez GE, Lecca L, Calderón RI, Coit J, Milstein M, Osso E, Jimenez J, Tintaya K, Garavito ES, Vasquez DV, Mitnick CD, Davies G.

Antimicrob Agents Chemother. 2017 Aug 24;61(9). pii: e01524-17. doi: 10.1128/AAC.01524-17. Print 2017 Sep. No abstract available.

25.

Reply to Srivastava et al., "pH Conditions under Which Pyrazinamide Works in Humans".

Kempker RR, Peloquin CA, Blumberg HM, Vashakidze S.

Antimicrob Agents Chemother. 2017 Aug 24;61(9). pii: e01120-17. doi: 10.1128/AAC.01120-17. Print 2017 Sep. No abstract available.

26.

Rifampin vs. rifapentine: what is the preferred rifamycin for tuberculosis?

Alfarisi O, Alghamdi WA, Al-Shaer MH, Dooley KE, Peloquin CA.

Expert Rev Clin Pharmacol. 2017 Oct;10(10):1027-1036. doi: 10.1080/17512433.2017.1366311. Epub 2017 Aug 18. Review.

PMID:
28803492
27.

Polymyxin Combinations Combat Escherichia coli Harboring mcr-1 and blaNDM-5: Preparation for a Postantibiotic Era.

Bulman ZP, Chen L, Walsh TJ, Satlin MJ, Qian Y, Bulitta JB, Peloquin CA, Holden PN, Nation RL, Li J, Kreiswirth BN, Tsuji BT.

MBio. 2017 Jul 25;8(4). pii: e00540-17. doi: 10.1128/mBio.00540-17.

28.

Population Pharmacokinetics of AZD-5847 in Adults with Pulmonary Tuberculosis.

Alsultan A, Furin JJ, Du Bois J, van Brakel E, Chheng P, Venter A, Thiel B, Debanne SA, Boom WH, Diacon AH, Johnson JL, Peloquin CA.

Antimicrob Agents Chemother. 2017 Sep 22;61(10). pii: e01066-17. doi: 10.1128/AAC.01066-17. Print 2017 Oct. Erratum in: Antimicrob Agents Chemother. 2017 Dec 21;62(1):.

29.

Evaluation of the Adequacy of the 2010 Revised World Health Organization Recommended Dosages of the First-line Antituberculosis Drugs for Children: Adequacy of Revised Dosages of TB Drugs for Children.

Yang H, Enimil A, Gillani FS, Antwi S, Dompreh A, Ortsin A, Adu Awhireng E, Owusu M, Wiesner L, Peloquin CA, Kwara A.

Pediatr Infect Dis J. 2018 Jan;37(1):43-51. doi: 10.1097/INF.0000000000001687.

PMID:
28719501
30.

Pharmacokinetic Evidence from the HIRIF Trial To Support Increased Doses of Rifampin for Tuberculosis.

Peloquin CA, Velásquez GE, Lecca L, Calderón RI, Coit J, Milstein M, Osso E, Jimenez J, Tintaya K, Sanchez Garavito E, Vargas Vasquez D, Mitnick CD, Davies G.

Antimicrob Agents Chemother. 2017 Jul 25;61(8). pii: e00038-17. doi: 10.1128/AAC.00038-17. Print 2017 Aug. Erratum in: Antimicrob Agents Chemother. 2017 Aug 24;61(9):.

31.

Stability of Second-Line Tuberculosis Medications Mixed With Milk or Yogurt.

Harausz EP, Leigh J, Garcia-Prats AJ, Furin J, Peloquin CA.

Clin Infect Dis. 2017 Aug 15;65(4):704-705. doi: 10.1093/cid/cix434. No abstract available.

PMID:
28482036
32.

Lung Tissue Concentrations of Pyrazinamide among Patients with Drug-Resistant Pulmonary Tuberculosis.

Kempker RR, Heinrichs MT, Nikolaishvili K, Sabulua I, Bablishvili N, Gogishvili S, Avaliani Z, Tukvadze N, Little B, Bernheim A, Read TD, Guarner J, Derendorf H, Peloquin CA, Blumberg HM, Vashakidze S.

Antimicrob Agents Chemother. 2017 May 24;61(6). pii: e00226-17. doi: 10.1128/AAC.00226-17. Print 2017 Jun.

33.

Impact of the CYP2C19 genotype on voriconazole exposure in adults with invasive fungal infections.

Hamadeh IS, Klinker KP, Borgert SJ, Richards AI, Li W, Mangal N, Hiemenz JW, Schmidt S, Langaee TY, Peloquin CA, Johnson JA, Cavallari LH.

Pharmacogenet Genomics. 2017 May;27(5):190-196. doi: 10.1097/FPC.0000000000000277.

34.

Population Pharmacokinetics of Pyrazinamide in Patients with Tuberculosis.

Alsultan A, Savic R, Dooley KE, Weiner M, Whitworth W, Mac Kenzie WR, Peloquin CA; Tuberculosis Trials Consortium.

Antimicrob Agents Chemother. 2017 May 24;61(6). pii: e02625-16. doi: 10.1128/AAC.02625-16. Print 2017 Jun.

35.

Mycobacterium tuberculosis Infection among Asian Elephants in Captivity.

Simpson G, Zimmerman R, Shashkina E, Chen L, Richard M, Bradford CM, Dragoo GA, Saiers RL, Peloquin CA, Daley CL, Planet P, Narachenia A, Mathema B, Kreiswirth BN.

Emerg Infect Dis. 2017 Mar;23(3):513-516. doi: 10.3201/eid2303.160726.

36.

Pharmacokinetics and pharmacodynamics of isoniazid in patients with intermediate resistance.

Alsultan A, Peloquin CA.

Int J Tuberc Lung Dis. 2017 Jan 1;21(1):121-123. doi: 10.5588/ijtld.16.0689. No abstract available.

PMID:
28157477
37.

Defining the optimal dose of rifapentine for pulmonary tuberculosis: Exposure-response relations from two phase II clinical trials.

Savic RM, Weiner M, MacKenzie WR, Engle M, Whitworth WC, Johnson JL, Nsubuga P, Nahid P, Nguyen NV, Peloquin CA, Dooley KE, Dorman SE; Tuberculosis Trials Consortium of the Centers for Disease Control and Prevention.

Clin Pharmacol Ther. 2017 Aug;102(2):321-331. doi: 10.1002/cpt.634. Epub 2017 Mar 2.

38.

Pharmacokinetics of the First-Line Antituberculosis Drugs in Ghanaian Children with Tuberculosis with or without HIV Coinfection.

Antwi S, Yang H, Enimil A, Sarfo AM, Gillani FS, Ansong D, Dompreh A, Orstin A, Opoku T, Bosomtwe D, Wiesner L, Norman J, Peloquin CA, Kwara A.

Antimicrob Agents Chemother. 2017 Jan 24;61(2). pii: e01701-16. doi: 10.1128/AAC.01701-16. Print 2017 Feb.

39.

The pharmacological challenges of treating tuberculosis and HIV coinfections.

Egelund EF, Dupree L, Huesgen E, Peloquin CA.

Expert Rev Clin Pharmacol. 2017 Feb;10(2):213-223. doi: 10.1080/17512433.2017.1259066. Epub 2016 Nov 28.

PMID:
27828731
40.

Reply to Alffenaar et al.

Peloquin CA, Dorman SE, Vernon A, Battista Migliori G, Nahid P.

Clin Infect Dis. 2017 Jan 1;64(1):105-106. Epub 2016 Oct 26. No abstract available.

PMID:
27789610
41.

ISONIAZID AND RIFAMPIN PHARMACOKINETICS IN TWO ASIAN ELEPHANTS (ELEPHAS MAXIMUS) INFECTED WITH MYCOBACTERIUM TUBERCULOSIS.

Egelund EF, Isaza R, Alsultan A, Peloquin CA.

J Zoo Wildl Med. 2016 Sep;47(3):868-871.

PMID:
27691967
42.

Executive Summary: Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis.

Nahid P, Dorman SE, Alipanah N, Barry PM, Brozek JL, Cattamanchi A, Chaisson LH, Chaisson RE, Daley CL, Grzemska M, Higashi JM, Ho CS, Hopewell PC, Keshavjee SA, Lienhardt C, Menzies R, Merrifield C, Narita M, O'Brien R, Peloquin CA, Raftery A, Saukkonen J, Schaaf HS, Sotgiu G, Starke JR, Migliori GB, Vernon A.

Clin Infect Dis. 2016 Oct 1;63(7):853-67. doi: 10.1093/cid/ciw566.

PMID:
27621353
43.

Early Bactericidal Activity of AZD5847 in Patients with Pulmonary Tuberculosis.

Furin JJ, Du Bois J, van Brakel E, Chheng P, Venter A, Peloquin CA, Alsultan A, Thiel BA, Debanne SM, Boom WH, Diacon AH, Johnson JL.

Antimicrob Agents Chemother. 2016 Oct 21;60(11):6591-6599. doi: 10.1128/AAC.01163-16. Print 2016 Nov.

44.

Rifapentine for the treatment of latent tuberculosis.

Egelund EF, Peloquin CA.

Expert Rev Clin Pharmacol. 2016 Aug 22:1-9. [Epub ahead of print]

PMID:
27545595
45.

Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis.

Nahid P, Dorman SE, Alipanah N, Barry PM, Brozek JL, Cattamanchi A, Chaisson LH, Chaisson RE, Daley CL, Grzemska M, Higashi JM, Ho CS, Hopewell PC, Keshavjee SA, Lienhardt C, Menzies R, Merrifield C, Narita M, O'Brien R, Peloquin CA, Raftery A, Saukkonen J, Schaaf HS, Sotgiu G, Starke JR, Migliori GB, Vernon A.

Clin Infect Dis. 2016 Oct 1;63(7):e147-e195. doi: 10.1093/cid/ciw376. Epub 2016 Aug 10.

PMID:
27516382
46.

Tuberculosis therapy for 2016 and beyond.

Lauzardo M, Peloquin CA.

Expert Opin Pharmacother. 2016 Oct;17(14):1859-72. doi: 10.1080/14656566.2016.1215428. Epub 2016 Aug 19. Review.

PMID:
27457206
47.

Urine colorimetry to detect Low rifampin exposure during tuberculosis therapy: a proof-of-concept study.

Zentner I, Schlecht HP, Khensouvann L, Tamuhla N, Kutzler M, Ivaturi V, Pasipanodya JG, Gumbo T, Peloquin CA, Bisson GP, Vinnard C.

BMC Infect Dis. 2016 Jun 1;16:242. doi: 10.1186/s12879-016-1576-1.

48.

Voriconazole pharmacokinetics following HSCT: results from the BMT CTN 0101 trial.

Hope WW, Walsh TJ, Goodwin J, Peloquin CA, Howard A, Kurtzberg J, Mendizabal A, Confer DL, Bulitta J, Baden LR, Neely MN, Wingard JR; Blood and Marrow Transplant Clinical Trials Network.

J Antimicrob Chemother. 2016 Aug;71(8):2234-40. doi: 10.1093/jac/dkw127. Epub 2016 Apr 27.

49.

Steady-state pharmacokinetics of oral linezolid suspension in a premature infant with osteomyelitis.

Banniettis N, Sharma R, Hand I, Peloquin CA, Kohlhoff S, Hammerschlag MR.

J Antimicrob Chemother. 2016 Jun;71(6):1738. doi: 10.1093/jac/dkv507. Epub 2016 Feb 6. No abstract available.

PMID:
26851607
50.

Population pharmacokinetic drug-drug interaction pooled analysis of existing data for rifabutin and HIV PIs.

Hennig S, Svensson EM, Niebecker R, Fourie PB, Weiner MH, Bonora S, Peloquin CA, Gallicano K, Flexner C, Pym A, Vis P, Olliaro PL, McIlleron H, Karlsson MO.

J Antimicrob Chemother. 2016 May;71(5):1330-40. doi: 10.1093/jac/dkv470. Epub 2016 Jan 31.

Supplemental Content

Loading ...
Support Center